You are here: Industry Insights > Biktarvy

News List

Biktarvy® shows high efficacy against HIV in real-world setting EuropeanPharmaceuticalReview
November 04, 2021
Gilead has announced interim results from the ongoing, multinational, observational single-arm, non-comparative real-world cohort BICSTaR study, designed to evaluate the antiviral effectiveness and safety profile of Biktarvy®...
Veklury Drives 2Q Growth for Gilead contractpharma
August 02, 2021
Veklury (remdesivir) with sales of $829 million offsets loss of exclusivity of Truvada and Atripla in the U.S. with sales down 72% and 42%, respectively.
Gilead’s HIV therapy Biktarvy demonstrates long-term sustained efficacy pharmatimes
March 08, 2021
Gilead Sciences has revealed new, four-year data from two Phase III studies evaluating Biktarvy for the treatment of HIV-1 in treatment-naïve adults.
China NMPA approves Biktarvy to treat HIV-1 Infection biospectrumasia
August 18, 2019
Biktarvy demonstrated high efficacy and a high barrier to resistance in clinical trials through 48 weeks
Biktarvy approved for the treatment of HIV-1 infection europeanpharmaceuticalreview
April 29, 2019
Biktarvy approved for the treatment of HIV-1 infection
Switching to Gilead's Biktarvy proves non-inferior in HIV patients pharmafile
March 07, 2018
Gilead has unveiled findings from two Phase 3 studies into the efficacy of switching to its three-drug combo Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) from a range of regimens.
Gilead's Biktarvy wins megablockbuster HIV nod fiercepharma
February 09, 2018
and rival GlaxoSmithKline strikes back...